Pacira to raise $63m more as Exparel reaches the market and seeks new indication
This article was originally published in Scrip
Executive Summary
The US specialty pharmaceutical company Pacira Pharmaceuticals has launched the analgesic formulation Exparel (bupivacaine liposome injectable suspension), and priced a common stock offering at $9.75 per share to raise up to $62.9 million in net proceeds, all in the space of a week.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.